Mingjian Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mingjian Zhao has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- He Bai
Department of General Surgery, The Second Hospital of Dalian Medical University, Dalian 116000, China
1 shared publication - Jifeng Liu
Department of General Surgery, The First Affiliated Hospital of Dalian Medical University, Dalian 116000, China
1 shared publication - Jingyuan Ma
The First Clinical Medical College, Liaoning University of Traditional Chinese Medicine
1 shared publication - Xing Wan
Clinical Laboratory of Integrative Medicine, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
1 shared publication - Xuyang Hu
The Second Clinical Medical College, Liaoning University of Traditional Chinese Medicine, Shenyang 110033, China
1 shared publication - Yanna Ma
The First Clinical Medical College, Liaoning University of Traditional Chinese Medicine, Shenyang 110033, China
1 shared publication
Latest Publications
- Open Access
- 17 January 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (1) , 140
Drug Advances in NAFLD: Individual and Combination Treatment Strategies of Natural Products and Small-Synthetic-Molecule Drugs
Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease and is closely associated with metabolic diseases such as obesity, type 2 diabetes mellitus (T2DM), and metabolic syndrome. However, effective treatment strategies for NAFLD are still lacking. In recent years, progress has been made in understanding the pathogenesis of NAFLD, identifying multiple therapeutic targets and providing new directions for drug development. This review summarizes the recent advances in the treatment of NAFLD, focusing on the mechanisms of action of natural products, small-synthetic-molecule drugs, and combination therapy strategies. This review aims to provide new insights and strategies in treating NAFLD.
- 17 January 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (1) , 140
Open AccessDrug Advances in NAFLD: Individual and Combination Treatment Strategies of Natural Products and Small-Synthetic-Molecule Drugs
Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease and is closely associated with metabolic diseases such as obesity, type 2 diabetes mellitus (T2DM), and metabolic syndrome. However, effective treatment strategies for NAFLD are still lacking. In recent years, progress has been made in understanding the pathogenesis of NAFLD, identifying multiple therapeutic targets and providing new directions for drug development. This review summarizes the recent advances in the treatment of NAFLD, focusing on the mechanisms of action of natural products, small-synthetic-molecule drugs, and combination therapy strategies. This review aims to provide new insights and strategies in treating NAFLD.